Galderma received a Complete Response Letter (CRL) from the FDA for RelabotulinumtoxinA, its neuromodulator candidate positioned as a Botox alternative. A CRL signals the agency cannot approve the application in its current form and requires additional data or manufacturing corrections before resubmission.
Regulatory
Galderma Gets Complete Response Letter on RelabotulinumtoxinA — What Went Wrong
FDA rejects Galderma's Botox rival on first submission; company faces clinical or manufacturing gaps.
CRL signals additional data or manufacturing corrections required before resubmission.
This is a material setback for Galderma's injectables pipeline. While the company has not disclosed the specific deficiencies, CRLs typically stem from inadequate efficacy/safety data, manufacturing process concerns, or labeling issues. Galderma will need to address FDA feedback, conduct additional studies if required, and resubmit—a process that typically adds 12–24 months to market entry. For practices, this extends the competitive window for existing neuromodulators and delays any potential pricing pressure from a new entrant.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.